Spain throws out Panama tainted cough syrup case
Judge rules that there was no criminal intent on behalf of Spanish company
Panama said it will appeal a Spanish court's decision to dismiss an investigation into a public health case that saw hundreds of people in the isthmus nation die after taking cough syrup made from glycerin imported from China by a Barcelona-based firm.
High Court Judge Ismael Moreno ruled that there was no criminal intent on behalf of the Spanish company because its officials were not aware that the mixture was deadly.
In 2006, some 250 people died in Panama after taking the syrup, which contained glycerin that was not intended for human consumption. The ruling was issued on April 26 but wasn't made public until Monday.
"It is as if they had dismissed the rapeseed oil case," said Alejandro Sanvicente, a lawyer for the victims, making reference to the colza scandal in 1981, in which about 1,100 people died in Spain. For two years, the lawyer said, the families of the victims had been waiting for a hearing.
Moreno said in his ruling that the Spanish company Rasfer only acted "as a mediator" when it won a public contract for 9,000 kilos of glycerin.
The medicine was mixed by Panamanian health authorities.
Tu suscripción se está usando en otro dispositivo
¿Quieres añadir otro usuario a tu suscripción?
Si continúas leyendo en este dispositivo, no se podrá leer en el otro.
FlechaTu suscripción se está usando en otro dispositivo y solo puedes acceder a EL PAÍS desde un dispositivo a la vez.
Si quieres compartir tu cuenta, cambia tu suscripción a la modalidad Premium, así podrás añadir otro usuario. Cada uno accederá con su propia cuenta de email, lo que os permitirá personalizar vuestra experiencia en EL PAÍS.
En el caso de no saber quién está usando tu cuenta, te recomendamos cambiar tu contraseña aquí.
Si decides continuar compartiendo tu cuenta, este mensaje se mostrará en tu dispositivo y en el de la otra persona que está usando tu cuenta de forma indefinida, afectando a tu experiencia de lectura. Puedes consultar aquí los términos y condiciones de la suscripción digital.